News
24.10.24

Topadur Pharma AG announces CEO change

The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO to pursue new professional challenges.

Since taking on the role in 2023, Mr. Brenneisen has made significant progress in guiding the company toward a future-oriented strategy and fostering a cultural change in preparation for an IPO. The Board of Directors expresses its appreciation to Mr. Brenneisen for his dedication to the company.

His vision has laid a good foundation for the company’s growth and success. As active shareholder he will still stay connected to Topadur Pharma AG.

Chairman of the Board, Dr. Reto Naef, will take over direct corporate leadership of the company on an interim basis until a successor is appointed.

The Board wishes Mr. Brenneisen all the best for his future.

Download DocumentDokument herunterladen
1.7.21
Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

Read more
10.11.20
Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read more
7.9.23
News

TOPADUR has been selected as a TOP 100 Scale-up 2023 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.

Read more